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Introduction 
Treatment with corticosteroids is frequently indi- 
cated in patients with asthma and COPD. Among the 
well-known side-effects of these drugs are myopathy 
and atrophy of striated muscles (1). Continuously 
active muscles (e.g. the diaphragm) were believed to 
be spared from this complication. However, recent 
animal studies and clinical observations have shown 
that the diaphragm may be involved in this process as 
well. Since respiratory muscle function may be 
already compromised in these patients (especially 
in COPD), any further deterioration induced by 
treatment with corticosteroids may be of clinical 
importance. 
This review will focus on pathogenesis, clinical 
features and therapeutic options, with emphasis on 
patients with obstructive airways diseases. 
Patterns of Steroid-induced Muscular Changes 
ACUTE STEROID MYOPATHY 
Short-term high-dose steroid administration may 
cause acute myopathy and rhabdomyolysis (24). 
This rare complication has been observed in patients 
with acute severe asthma who were treated with e.g. 
hydrocortisone 34 g daily i.v. for 5-7 days. How- 
ever, acute myopathy has also been reported in 
asthmatics who never received more than 1 g of 
intravenous hydrocortisone daily (4). Administration 
of a total dose of hydrocortisone >5.4 increased the 
incidence of this complication, whereas no acute 
myopathy was observed with doses ~4 g (4). An 
association with concomitant use of paralytic agents 
has been suggested (5). 
*To whom all correspondence should be addressed at: Department 
of Pulmonary Diseases, Academic Hospital Nijmegen, PO Box 9101, 
6500 HB Nijmegen, The Netherlands. 
Pathological features include rhabdomyolysis, 
marked elevation of creatine kinase (CK), and focal 
or diffuse necrosis without predilection for a specific 
fibre type (2,3). Diffuse muscle weakness is the main 
clinical feature. Respiratory muscle involvement 
results in prolonged weaning after mechanical venti- 
lation. Recovery appears to be slow; electromyo- 
graphic signs of mild myopathy may persist up to 6 
months after clinical recovery (3). 
CHRONIC STEROID MYOPATHY 
The clinical pattern of chronic steroid myopathy 
consists of proximal muscle weakness, occurring after 
prolonged treatment with corticosteroids. There is a 
wide variation in duration of treatment and total 
dosage before symptoms of chronic steroid myopathy 
become evident. In general, however, muscle weak- 
ness may occur after treatment with prednisolone 
30-40 mg daily during more than 1 month (1). 
Symptoms vary from mild muscle weakness with no 
objective fall in strength to inability to raise the upper 
or lower limbs. Laboratory investigation shows nor- 
mal muscle enzymes, although LDH may be slightly 
elevated (6,7). The excretion of creatine is increased 
several days before muscle weakness appeairs. Myo- 
globinuria and rhabdomyolysis are absent. 
Biopsies from affected muscle reveal selective type 
IIb fibre atrophy (1,8), in contrast to the generalized 
fibre atrophy associated with acute steroid myop- 
athy. The recovery of weakness after chronic use of 
steroids may take weeks or months (1,7). 
Aetiology and Pathogenesis 
Fluorinated steroids such as triamcinolone and 
dexamethasone are more potent than non- 
fluorinated steroids (like prednisolone) in terms of 
anti-inflammatory and immunosuppressive actions 
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(9). Similarly, side-effects occur more frequently and 
are worse after treatment with fluorinated steroids. 
The cause of these differences is unknown. With 
regard to muscle damage, a difference in binding of 
triamcinolone, dexamethasone and cortisol to cyto- 
plasmatic proteins may contribute (10). 
Several pathways to explain the unfavourable 
effects of corticosteroids on striated muscle have been 
suggested. Treatment with steroids increases muscle 
glycogen by increasing muscle glycogen synthetase 
activity (1 l), while glycogen utilization is decreased 
(12). In addition, steroids induce protein wasting by a 
reduction in protein synthesis and an increase in 
intracellular proteolysis. Protein synthesis is primar- 
ily inhibited in type II fibres, mainly by regulating the 
activity of factors involved in peptide initiation (13). 
Increased muscle cytoplasmatic protease activity, 
associated with steroid treatment, results in myo- 
fibrillar destruction (10). Finally, mitochondrial 
alterations in muscles affected by steroids have sug- 
gested that impaired oxidative respiration may be 
an important factor in pathogenesis. The severity of 
steroid-induced changes correlated with the percent- 
age of type IIb fibres (1416). 
In this respect the diaphragm, mainly composed of 
type I and IIa fibres, would not be expected to be 
affected by corticosteroids. In addition, corticoster- 
oids preferentially affect less active muscles (17). 
Recent animal studies, however, have demonstrated 
that steroids indeed may affect diaphragm structure 
and function. 
Findings in Animal Models 
Animal models have been used to study respiratory 
muscle involvement in steroid myopathy. This 
affords the advantage of studying the isolated effects 
of corticosteroids on respiratory muscle structure and 
function without interference with (complications of) 
the underlying disease affecting respiratory muscle 
function. 
High doses of fluorinated steroids (e.g. triamcino- 
lone 1.2-5 mg kg- ’ day-‘, administered during 13 
weeks) caused type IIb muscle fibre atrophy, whereas 
type I and type IIa fibres were not affected (18-20). 
Vacuolar changes occurred in all fibre types. Glyco- 
gen levels in muscle cells were elevated. These histo- 
logical alterations led to changes in contractile 
properties. As a result of the selective type IIb fibre 
atrophy, the cross-sectional area of the diaphragm 
contained more slow (type I and IIa) muscle fibres. 
Therefore, the diaphragm showed the contractile 
profile of slow muscles, including prolonged contrac- 
tion time and half relaxation time, an upward shift of 
the force-frequency curve, and a reduction in fatig- 
ability. The observed loss in diaphragm mass, 
however, clearly decreased absolute force generation. 
Non-fluorinated steroids appeared to affect dia- 
phragm and function in a different way. Adminis- 
tration of the non-fluorinated steroid prednisolone 
(5 mg kg- ’ day- ’ during 4 weeks) caused myogenic 
changes, consisting of wider than normal variation of 
fibre sizes, excess of nuclei, scattered necrotic or 
atrophic fibres, and an increased amount of connec- 
tive tissue (21). No atrophy of type IIb fibres was 
observed. Examination of the contractile properties 
showed increased fatigability and a tendency towards 
lowered maximal tetanic tensions. These findings 
suggested that moderate doses of non-fluorinated 
steroids resulted in myopathy rather than in atrophy 
and affected the intrinsic contractile apparatus of the 
diaphragm. 
The functional consequences of these changes were 
addressed by the study of Nachazel and Palecek (22). 
They demonstrated in rats that PaCO, at rest was 
unaltered after administration of hydrocortisone 
60 mg kg- ’ during 8 days (22). The response to an 
increased ventilatory load, however, was clearly 
diminished in the steroid-treated animals. 
Clinical Findings 
In recent years, several reports have shown 
involvement of respiratory muscles in chronic steroid 
myopathy (Table 1). Janssens and Decramer (23) 
reported two patients with connective tissue disease 
receiving prednisone 30-50 mg daily who complained 
of muscle weakness and dyspnoea. Maximal inspira- 
tory (PImax) and expiratory mouth pressures 
(Pnmax) were decreased. After gradual reduction of 
the steroid dose, Prmax and PEmax markedly 
increased. Similar changes in PImax and PEmax and 
in quadriceps force were described during prolonged 
treatment with high doses of corticosteroids in two 
patients with asthma and one with COPD (7). 
In a group of 34 asthmatic steroid-dependent 
patients, no correlation was found between the mean 
dose of steroids in the last 8 years and respiratory 
and peripheral muscle strength (24). These, however, 
were outpatients on continuous treatment with low 
doses of steroids, and the effects of repetitive bursts, 
which might be more harmful, were not investigated. 
In a recent study, eight out of 21 consecutive patients 
who were admitted to hospital with acute exacerba- 
tions of COPD or asthma, suffered from generalized 
muscle weakness (25). In seven out of these eight 
patients the average daily dose of methylprednisolone 
during the last 6 months exceeded 4 mg, while this 
Ta
ble
 
I 
St
er
oid
 
tre
atm
en
t 
an
d 
mu
sc
le 
str
en
gth
 
in 
ch
ro
nic
 
ste
ro
id 
my
op
ath
y 
Re
fer
en
ce
 
Di
so
rd
er
 
No
. 
Ag
e 
(ye
a4
 
St
er
oid
s 
do
se
/da
y, 
du
ra
tio
n 
Pr
ma
x 
Pn
ma
x 
Pe
rip
he
ra
l 
mu
sc
le 
str
en
gth
 
W
an
g 
(56
) 
Ja
ns
se
ns
 
(23
) 
De
cra
me
r 
(7)
 
Bo
wy
er
 
(36
) 
he
alt
hy
 
su
bje
cts
 
co
nn
ec
tiv
e 
tis
su
e 
dis
ea
se
 
as
thm
a, 
CO
PD
 
as
thm
a 
Pi
ca
rd
o 
(24
) 
De
cra
me
r 
(25
) 
W
ein
er
 
(26
) 
as
thm
a 
as
thm
a, 
CO
PD
 
glo
me
ru
lo-
 
ne
ph
rit
is,
 
IT
P,
 
thy
ro
idi
tis
 
16
 2 3 60
 
34
 
21
 8 
19
-3
9 
50
, 
58
 
59
-6
4 
58
 z
!z 
7 
60
& 
13
 
26
 f
 
2 
pr
ed
nis
olo
ne
 
20
 m
g 
2 
we
ek
s 
pr
ed
nis
olo
ne
 
30
-5
0 
mg
 
10
 w
ee
ks
 
me
thy
lpr
ed
nis
olo
ne
 
30
-8
0 
mg
 
2-
12
 
we
ek
s 
pr
ed
nis
olo
ne
>4
0 
mg
 
<4
0 
mg
 
2 
we
ek
s-‘
ye
ars
’ 
pr
ed
nis
on
e 
12
 f 
4 
mg
 
8 
f 
4 
ye
ars
 
AD
D 
du
rin
g 
the
 
las
t 
6 
mo
nth
s 
pr
ed
nis
on
e 
61
 f 
7 
mg
 
du
rin
g 
8 
we
ek
s, 
fo
llo
we
d 
by
 
tap
er
ing
 
do
wn
 
to 
0 
wi
th
in 
6 
we
ek
s 
= 
= 1 
- 
1 
1 
1 
@
=3
) 
1 
n.p
. 
r 
= 
= 
= 
Y=
 - 
0.
64
* 
1, 
en
du
ra
nc
e 
1 
r=
-0
.41
* 
I= 
-0
,56
* 
- 
- 
Pr
ma
x: 
ma
xim
al 
ins
pir
ato
ry 
pre
ss
ure
; 
Pn
ma
x: 
ma
xim
al 
ex
pir
ato
ry 
pre
ss
ure
; 
=: 
no
 c
ha
ng
e; 
- 
: n
ot 
me
as
ur
ed
; 
n.p
.: 
no
t 
pu
bli
sh
ed
; 
AD
D:
 
av
er
ag
e 
da
ily
 
do
se
; 
*: 
co
rre
lat
ion
 
(r) 
wi
th
 
AD
D.
 
IT
P:
 
idi
op
at
hic
 
thr
om
bo
cy
top
en
ic 
pu
rp
ur
a. 
338 Topical Review 
was the case in only three out of the 13 patients with 
normal muscle strength. 
Another approach to assess the impact of steroids 
on respiratory muscle function is to study patients in 
whom the underlying disease does not affect the 
ventilatory pump. In such patients Weiner and 
coworkers (26) found substantial decreases in inspira- 
tory muscle strength and endurance during treatment 
with prednisolone l-l.5 mg kg- ’ day- ’ for 8 weeks. 
Tapering off the dose was followed by a gradual 
increase in respiratory muscle function, reaching 
baseline values 6 months after discontinuation. 
The above-mentioned studies suggest that abnor- 
malities in respiratory muscle function are likely to 
occur relatively frequently during prolonged treat- 
ment with corticosteroids. This is not surprising since 
myopathy of peripheral muscles is known to occur in 
20-65% of patients treated with steroids (1). Marked 
changes in respiratory muscle function, however, 
may occur before symptoms like dyspnoea and 
changes in pulmonary function and bloodgases 
become evident. In addition, respiratory muscle func- 
tion may be compromised in patients with severe 
COPD. This is caused by hyperinflation (27) malnu- 
trition (28,29), disturbances in bloodgases (30), car- 
diac failure (31,32), and physical inactivity (33). 
Therefore, the diaphragm may be more vulnerable 
for additional damage caused by steroids. On the 
other hand, this complex of unfavourable factors 
may hamper an accurate assessment of the contribu- 
tion of steroids to respiratory muscle dysfunction in 
the individual patient. Moreover, treatment with 
&sympathicomimetic drugs (34) and theophylline 
(35) may in part counteract the effects of steroids on 
respiratory muscle function. The above-mentioned 
arguments may explain the current lack of insight 
into the true incidence of steroid-induced respiratory 
muscle dysfunction. 
Diagnosis of Chronic Steroid Myopathy 
There are no specific tests to establish the diagnosis 
steroid-induced myopathy. The following findings 
may be of help. 
LABORATORY ABNORMALITIES 
Muscle enzymes are usually within the normal 
range. LDH may be slightly elevated (6,7). Myo- 
globinuria and rhabdomyolysis are absent (in con- 
trast to acute steroid myopathy). Urinary creatine 
excretion is strongly elevated, starting several days 
before the clinical appearance of myopathy (8,23). In 
addition, the course of the urine-creatine levels, in 
combination with the clinical recovery after discon- 
tinuation of the treatment with steroids, may support 
the diagnosis. 
MUSCLE FUNCTION TESTING 
Prmax and PEmax are frequently reduced in 
patients with COPD. Additional effects of corticos- 
teroids may be detected by serial measurements, 
combined with changes in steroid doses. As pointed 
out by the study of Weiner and coworkers (26), 
respiratory muscle dysfunction may also be detected 
by inspiratory muscle endurance testing by means of 
incremental threshold loading. Peripheral muscle 
strength testing may reveal lowered force in the 
extremities. Steroid-induced changes in respiratory 
and peripheral muscle strength appeared to be well 
correlated (7,25,36). 
PULMONARY FUNCTION TESTS 
In patients with steroid myopathy pulmonary 
function tests are similar to those observed in 
patients with respiratory muscle weakness due to 
other causes (37). Lung compliance is reduced with 
low recoil pressures at total lung capacity (TLC) (37). 
This is in contrast to the pattern observed in inter- 
stitial lung disease in which elastic recoil pressure at 
TLC is increased (38). If respiratory muscle strength 
falls below f 30% of predicted, lung volumes 
decrease (39) and arterial PCO, increases (40). 
ELECTROMYOGRAPHIC EXAMINATION (EMG) 
The EMG offers no discrimination between steroid 
myopathy and myopathy due to other causes (1). The 
motor unit potentials are of low amplitude and short 
duration (8, 41). 
MUSCLE BIOPSY 
A peripheral muscle biopsy shows type IIb fibre 
atrophy without signs of inflammatory cells or myo- 
necrosis (1). A less specific finding is the presence of 
large numbers of glycogen granules in the intermyo- 
fibrillar spaces. Muscle biopsy can differentiate 
between muscle weakness due to steroid myopathy 
and malnutrition, since malnutrition is associated 
with generalized muscle fibre atrophy (42-44). 
Treatment of Corticosteroid-induced Myopathy 
If steroid myopathy occurs during treatment with 
fluorinated steroids, the alternative is to switch to 
non-fluorinated steroids such as prednisolone or 
methylprednisolone. When non-fluorinated steroids 
are the cause of steroid myopathy, the dose should be 
tapered off. If this is not possible, therapeutic inter- 
ventions to antagonize steroid-induced myopathy 
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may be considered. Potentially useful strategies have 
been studied in experimental models, but they have 
not yet been confirmed by clinical studies. 
EXERCISE 
An increase in glucocorticoid receptors in immobil- 
ized muscles has been reported (45). Subsequently, 
animal studies showed that exercise may impede 
steroid-induced muscle atrophy (46,47). 
ANABOLIC STEROIDS 
Administration of anabolic steroids in normal 
male rats increased the mass of respiratory muscles in 
proportion to body weight (48,49). A reduction in 
corticosteroid-induced weight loss due to the supple- 
tion of anabolic steroids has been observed (50,51). 
This is possibly caused by an interaction on gluco- 
corticoid receptor level (52). 
GROWTHHORMONE 
An increase in mass of the ‘malnourished’ dia- 
phragm in rats was accelerated by the administration 
of growth hormone (53). If this drug may counteract 
steroid-induced changes is unknown. 
82-~~~~~Ts AND THEOPHYLLINE 
Clenbuterol reduces protein degradation, possibly 
accompanied by a simultaneous increase in protein 
synthesis. Administration of clenbuterol alone (54) or 
combined with growth hormone (55) increased both 
type IIa and IIb fibre size. In normal subjects, 
Martineau et al. (34) observed an increase in peri- 
pheral muscle strength and inspiratory mouth press- 
ure after administration of 8 mg salbutamol twice 
daily for 3 weeks. Similarly, theophylline may 
improve respiratory muscle function in patients with 
COPD (35), but its role in preventing steroid-induced 
respiratory muscle dysfunction is not clear. 
Conclusions 
The incidence of involvement of the respiratory 
muscles in chronic steroid myopathy is unknown at 
present, although it may be quite common. Current 
therapy with positive inotropic drugs such as theo- 
phylline and perhaps inhaled &agonists, might in 
part counteract this complication. Especially in 
patients with COPD, who already have impaired res- 
piratory muscle function, diagnosing steroid myop- 
athy with respiratory muscle involvement is difficult 
but essential. If chronic steroid myopathy is consid- 
ered, peripheral and respiratory muscle strength, uri- 
nary creatine excretion, and serum muscle enzymes 
should be measured. Pulmonary function tests and 
peripheral muscle biopsy may provide additional 
information. Treatment of corticosteroid-induced 
myopathy consists of tapering off the dose of steroids 
or switching to non-fluorinated steroids. Other thera- 
peutic interventions are being studied. 
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